← All trials
NCT04447326
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2026
- First posted
- Jun 25, 2020
- Last posted
- Jun 25, 2020
- Enrollment
- 106
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hacettepe UniversityLead sponsor
- Central South UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Hacettepe UniversityReponsible party - principal investigator
- Shandong UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- North Sichuan Medical UniversityCollaborator
- Jiangxi Provincial Cancer HospitalCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Guangxi Medical UniversityCollaborator
- Guilin Medical UniversityCollaborator
- LiuZhou People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.